Cargando…
Heart Failure and Stroke
PURPOSE: Ischemic stroke significantly contributes to morbidity and mortality in heart failure (HF). The risk of stroke increases significantly, with coexisting atrial fibrillation (AF). An aggravating factor could be asymptomatic paroxysms of AF (so-called silent AF), and therefore, the risk strati...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132785/ https://www.ncbi.nlm.nih.gov/pubmed/30062623 http://dx.doi.org/10.1007/s11897-018-0405-9 |
_version_ | 1783354385446731776 |
---|---|
author | Schumacher, Katja Kornej, Jelena Shantsila, Eduard Lip, Gregory Y. H. |
author_facet | Schumacher, Katja Kornej, Jelena Shantsila, Eduard Lip, Gregory Y. H. |
author_sort | Schumacher, Katja |
collection | PubMed |
description | PURPOSE: Ischemic stroke significantly contributes to morbidity and mortality in heart failure (HF). The risk of stroke increases significantly, with coexisting atrial fibrillation (AF). An aggravating factor could be asymptomatic paroxysms of AF (so-called silent AF), and therefore, the risk stratification in these patients remains difficult. This review provides an overview of stroke risk in HF, its risk stratification, and stroke prevention in these patients. RECENT FINDINGS: Stroke risk stratification in HF patients remains an important issue. Recently, the CHA(2)DS(2)-VASc score, originally developed to predict stroke risk in AF patients, had been reported to be a predictive for strokes in HF patients regardless of AF being present. Furthermore, there are several independent risk factors (e.g., hypertension, diabetes mellitus, prior stroke) described. SUMMARY: Based on the current evidence, HF should be considered as an independent risk factor for stroke. The CHA(2)DS(2)-VASc score might be useful to predict stroke risk in HF patients with or without AF in clinical routine. However, there is only a recommendation for the oral anticoagulation use in patients with concomitant HF and AF, while in patients with HF and no AF, individualized risk stratification is preferred. Current guidelines recommend to prefer non-vitamin Kantagonist anticoagulants over warfarin. |
format | Online Article Text |
id | pubmed-6132785 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-61327852018-09-13 Heart Failure and Stroke Schumacher, Katja Kornej, Jelena Shantsila, Eduard Lip, Gregory Y. H. Curr Heart Fail Rep Comorbidities of Heart Failure (C Angermann, Section Editor) PURPOSE: Ischemic stroke significantly contributes to morbidity and mortality in heart failure (HF). The risk of stroke increases significantly, with coexisting atrial fibrillation (AF). An aggravating factor could be asymptomatic paroxysms of AF (so-called silent AF), and therefore, the risk stratification in these patients remains difficult. This review provides an overview of stroke risk in HF, its risk stratification, and stroke prevention in these patients. RECENT FINDINGS: Stroke risk stratification in HF patients remains an important issue. Recently, the CHA(2)DS(2)-VASc score, originally developed to predict stroke risk in AF patients, had been reported to be a predictive for strokes in HF patients regardless of AF being present. Furthermore, there are several independent risk factors (e.g., hypertension, diabetes mellitus, prior stroke) described. SUMMARY: Based on the current evidence, HF should be considered as an independent risk factor for stroke. The CHA(2)DS(2)-VASc score might be useful to predict stroke risk in HF patients with or without AF in clinical routine. However, there is only a recommendation for the oral anticoagulation use in patients with concomitant HF and AF, while in patients with HF and no AF, individualized risk stratification is preferred. Current guidelines recommend to prefer non-vitamin Kantagonist anticoagulants over warfarin. Springer US 2018-07-30 2018 /pmc/articles/PMC6132785/ /pubmed/30062623 http://dx.doi.org/10.1007/s11897-018-0405-9 Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Comorbidities of Heart Failure (C Angermann, Section Editor) Schumacher, Katja Kornej, Jelena Shantsila, Eduard Lip, Gregory Y. H. Heart Failure and Stroke |
title | Heart Failure and Stroke |
title_full | Heart Failure and Stroke |
title_fullStr | Heart Failure and Stroke |
title_full_unstemmed | Heart Failure and Stroke |
title_short | Heart Failure and Stroke |
title_sort | heart failure and stroke |
topic | Comorbidities of Heart Failure (C Angermann, Section Editor) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132785/ https://www.ncbi.nlm.nih.gov/pubmed/30062623 http://dx.doi.org/10.1007/s11897-018-0405-9 |
work_keys_str_mv | AT schumacherkatja heartfailureandstroke AT kornejjelena heartfailureandstroke AT shantsilaeduard heartfailureandstroke AT lipgregoryyh heartfailureandstroke |